Disease · MONDO_0024331
Targets178
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
1 to 20 of 178
Download this page as JSON| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| KDR | Vascular endothelial growth factor receptor | 11 | Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/3791 | Drugs and targets |
| FLT4 | Vascular endothelial growth factor receptor | 8 | Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/2324 | Drugs and targets |
| FLT1 | Vascular endothelial growth factor receptor | 7 | Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/2321 | Drugs and targets |
| PDCD1 | Programmed cell death protein 1 | 7 | Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor | Phase 3 | https://conductscience.org/library/genes/5133 | Drugs and targets |
| PDGFRB | Platelet-derived growth factor receptor | 6 | Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor | Phase 2/3 | https://conductscience.org/library/genes/5159 | Drugs and targets |
| EGFR | Epidermal growth factor receptor | 5 | Epidermal growth factor receptor erbB1 antagonist; Epidermal growth factor receptor erbB1 inhibitor | Approval | https://conductscience.org/library/genes/1956 | Drugs and targets |
| KIT | Mast/stem cell growth factor receptor Kit | 5 | Stem cell growth factor receptor inhibitor | Phase 2/3 | https://conductscience.org/library/genes/3815 | Drugs and targets |
| BRAF | Serine/threonine-protein kinase B-raf | 4 | Serine/threonine-protein kinase B-raf inhibitor | Phase 2/3 | https://conductscience.org/library/genes/673 | Drugs and targets |
| FGFR1 | Fibroblast growth factor receptor | 4 | Fibroblast growth factor receptor 1 inhibitor; Fibroblast growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/2260 | Drugs and targets |
| PDGFRA | Platelet-derived growth factor receptor | 4 | Platelet-derived growth factor receptor alpha inhibitor; Platelet-derived growth factor receptor inhibitor | Phase 2/3 | https://conductscience.org/library/genes/5156 | Drugs and targets |
| TYMS | Thymidylate synthase | 4 | Thymidylate synthase inhibitor | Phase 3 | https://conductscience.org/library/genes/7298 | Drugs and targets |
| CD274 | Programmed cell death 1 ligand 1 | 3 | Programmed cell death 1 ligand 1 binding agent; Programmed cell death 1 ligand 1 inhibitor | Phase 2 | https://conductscience.org/library/genes/29126 | Drugs and targets |
| FGFR2 | Fibroblast growth factor receptor | 3 | Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/2263 | Drugs and targets |
| FGFR3 | Fibroblast growth factor receptor | 3 | Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/2261 | Drugs and targets |
| FLT3 | Receptor-type tyrosine-protein kinase FLT3 | 3 | Tyrosine-protein kinase receptor FLT3 inhibitor | Phase 2/3 | https://conductscience.org/library/genes/2322 | Drugs and targets |
| MAP2K1 | Dual specificity mitogen-activated protein kinase kinase 1 | 3 | Dual specificity mitogen-activated protein kinase kinase 1 inhibitor | Phase 2 | https://conductscience.org/library/genes/5604 | Drugs and targets |
| MAP2K2 | Dual specificity mitogen-activated protein kinase kinase 2 | 3 | Dual specificity mitogen-activated protein kinase kinase 2 inhibitor | Phase 2 | https://conductscience.org/library/genes/5605 | Drugs and targets |
| RET | Proto-oncogene tyrosine-protein kinase receptor Ret | 3 | Tyrosine-protein kinase receptor RET inhibitor | Phase 2/3 | https://conductscience.org/library/genes/5979 | Drugs and targets |
| TOP1 | DNA topoisomerase 1 | 3 | DNA topoisomerase I inhibitor | Phase 3 | https://conductscience.org/library/genes/7150 | Drugs and targets |
| CRBN | CRL4(CRBN) E3 ubiquitin ligase | 2 | CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator | Phase 2 | https://conductscience.org/library/genes/51185 | Drugs and targets |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0024331/targets